Fidaxomicin for Clostridium difficile-Associated Diarrhoea: Epidemiological Method for Estimation of Warranted Price

Background: Fidaxomicin is a macrocyclic antibiotic approved in 2011 by the US Food and Drug Administration for treatment of Clostridium difficile-associated diarrhoea (CDAD). Objective: Herein, we present an epidemiological method to estimate, on a case mix basis, and from the perspective of the US...

Descripción completa

Detalles Bibliográficos
Autores principales: Sclar, David Alexander, Robison, Linda M., Oganov, Ambartsum M., Schmidt, Jennifer M., Bowen, Kurt A., Castillo, Leigh V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2012
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3742423/
https://www.ncbi.nlm.nih.gov/pubmed/22708825
http://dx.doi.org/10.1007/BF03261906

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3742423/
https://www.ncbi.nlm.nih.gov/pubmed/22708825
http://dx.doi.org/10.1007/BF03261906

Ejemplares similares